Analysis
Rightway Healthcare, the New York-based healthcare navigation and pharmacy benefits management startup, closed a $155 million financing round with no accompanying press release, according to an SEC filing reported by AlleyWatch on September 9. The filing lists six investors but names none of them, and doesn't disclose a post-money valuation -- a notably quieter rollout than Rightway's prior rounds.
Founded in 2017 by brothers Jordan and Theodore Feldman, Rightway builds a platform employers use to help employees navigate medical and prescription-drug decisions, positioning itself as a leaner, more transparent alternative to the traditional pharmacy benefit manager model dominated by CVS Caremark, Express Scripts and OptumRx. The company was last known to be valued around $1.1 billion and has now raised close to $400 million in total disclosed funding.
Why the quiet rollout matters
The silence around this round is itself the story. A $155 million raise with no named lead, no valuation, and no announcement could mean several different things: a bridge extension from existing holders rather than a new institutional round, a strategic investor with confidentiality terms, or a traditional round still being finalized before a public unveiling. Companies raising at flat or down valuations sometimes choose exactly this kind of quiet SEC-filing-only disclosure rather than a press cycle that invites scrutiny of the terms.
Rightway operates in a PBM-disruption category that has drawn scrutiny well beyond venture capital -- the traditional PBM oligopoly of CVS Caremark, Express Scripts and OptumRx together controls roughly 80% of the US market and has faced FTC investigations into rebate practices for the past two years. A well-funded challenger with employer-direct relationships is a real structural threat to that concentration, but Rightway's own funding opacity this round makes it harder for outside observers to judge whether the company is scaling from strength or raising defensively.
Jordan and Theodore Feldman built Rightway after working in venture capital and consulting respectively, betting that employers wanted a PBM alternative that made money on service fees rather than opaque drug-rebate spreads -- the practice that has drawn the most regulatory scrutiny toward CVS Caremark, Express Scripts and OptumRx. Several states, including Arkansas and Oklahoma, have already passed laws restricting PBM rebate practices or requiring divestiture of pharmacy ownership, and the FTC's own interim staff report on PBM practices, released in 2024, found evidence the largest three PBMs use their market power to squeeze independent pharmacies and inflate costs for certain specialty drugs.
The regulatory tailwind
That regulatory backdrop is exactly what gives a well-capitalized challenger like Rightway room to grow -- large employers increasingly want a PBM relationship that doesn't carry the same rebate-transparency risk the incumbents face from state attorneys general and the FTC. But regulatory tailwinds for the category don't explain why this specific round went unannounced, and until Rightway or an investor confirms who actually wrote the checks, the healthiest read and the defensive read both remain equally plausible from the outside.
Whatever the round's structure, Rightway's continued ability to raise at all -- quietly or not -- is itself a data point in a healthtech funding environment that has otherwise cooled considerably from its 2021 peak, when digital-health startups of every stripe could raise nine-figure rounds on growth metrics alone. A 2026 healthtech round of this size getting done without a press cycle suggests either genuine investor conviction that doesn't need marketing validation, or a company managing the narrative around a harder fundraising environment than its top-line growth numbers would suggest.
